American Society of Hematology

Fig. 7.

$Fig. 7. Effect of anti-TNFα neutralizing antibody in LTBMCs. / Exogenously added mouse antihuman TNFα neutralizing antibody in LTBMCs at a dose of 1.8 μg/mL per week significantly increased the number of CFCs in those patients with RA studied prior to in vivo anti-TNFα treatment (A) but not in patients studied after treatment (B). Data points represent the mean CFC number (± SEM) in the nonadherent cell fraction of LTBMCs from patients with RA before (n = 7) or after (n = 3) in vivo anti-TNFα treatment. Comparison between treated and untreated with neutralizing antibody cultures was performed using the 2-way analysis of variance test.$

Effect of anti-TNFα neutralizing antibody in LTBMCs.

Exogenously added mouse antihuman TNFα neutralizing antibody in LTBMCs at a dose of 1.8 μg/mL per week significantly increased the number of CFCs in those patients with RA studied prior to in vivo anti-TNFα treatment (A) but not in patients studied after treatment (B). Data points represent the mean CFC number (± SEM) in the nonadherent cell fraction of LTBMCs from patients with RA before (n = 7) or after (n = 3) in vivo anti-TNFα treatment. Comparison between treated and untreated with neutralizing antibody cultures was performed using the 2-way analysis of variance test.

This Feature Is Available To Subscribers Only